Vertex Second Phase II Study Supports Telaprevir 24-Week Regimen
This article was originally published in The Pink Sheet Daily
Executive Summary
Adverse events associated with the hep C treatment are “troublesome,” not “troubling,” Vertex CEO Boger says.